Trial Design Can' t Detect Heterogeneity in Hypertension Tre
Conventional clinical trials are unable to detect clinically important heterogeneity in intensive blood pressure (BP) treatment effects, according to a modeling study published online in the Annals of Internal Medicine.

Sanjay Basu, MD, PhD, from Stanford University in Palo Alto, Calif., and colleagues performed a theoretical modeling study in a population of US adults to identify whether large, clinically important differences in benefit and harm can be hidden among patients (heterogeneous treatment effects [HTEs]) in BP trials. The authors used data from 2 trials comparing standard with intensive BP treatment and from the National Health and Nutrition Examination Survey 2013 to 2014.